ADPT has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
ADPT has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Adaptive Biotechnologies's EPS without NRI for the three months ended in Mar. 2024 was $-0.33.
During the past 3 years, the average EPS without NRI Growth Rate was -7.60% per year. During the past 5 years, the average EPS without NRI Growth Rate was -22.20% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EPS without NRI growth rate.
During the past 7 years, the highest 3-Year average EPS without NRI Growth Rate of Adaptive Biotechnologies was -7.60% per year. The lowest was -49.90% per year. And the median was -26.20% per year.
For the Biotechnology subindustry, Adaptive Biotechnologies's 3-Year EPS without NRI Growth Rate, along with its competitors' market caps and 3-Year EPS without NRI Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, Adaptive Biotechnologies's 3-Year EPS without NRI Growth Rate distribution charts can be found below:
* The bar in red indicates where Adaptive Biotechnologies's 3-Year EPS without NRI Growth Rate falls into.
This is the 3-year average growth rate of EPS without NRI. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EPS without NRI growth rate.
Adaptive Biotechnologies (NAS:ADPT) 3-Year EPS without NRI Growth Rate Explanation
EPS without NRI is the amount of earnings without non-recurring items per outstanding share of the company's stock.
Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists Earnings per share without Non-Recurring Items, which better reflects the company's underlying performance.
Thank you for viewing the detailed overview of Adaptive Biotechnologies's 3-Year EPS without NRI Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.
Kyle Piskel | officer: Principal Accounting Officer | C/O ADAPTIVE BIOTECHNOLOGIES CORPORATION, 1551 EASTLAKE AVE E STE 200, SEATTLE WA 98102 |
Nitin Sood | officer: Chief Commercial Officer, MRD | C/O ADAPTIVE BIOTECHNOLOGIES CORPORATION, 1551 EASTLAKE AVE E STE 200, SEATTLE WA 98102 |
Tycho Peterson | officer: Chief Financial Officer | C/O ADAPTIVE BIOTECHNOLOGIES CORPORATION, 1165 EASTLAKE AVE E, SEATTLE WA 98109 |
R Mark Adams | officer: Chief Operating Officer | C/O ADAPTIVE BIOTECHNOLOGIES CORPORATION, 1551 EASTLAKE AVE E STE 200, SEATTLE WA 98102 |
Michelle Renee Griffin | director | 19723 NE 65TH LANE, KIRKLAND WA 98033 |
Stacy L Taylor | officer: SVP and General Counsel | C/O ADAPTIVE BIOTECHNOLOGIES CORPORATION, 1551 EASTLAKE AVENUE E SUITE 200, SEATTLE WA 98102 |
Leslie Trigg | director | C/O OUTSET MEDICAL, 1830 BERING ROAD, SAN JOSE CA 95112 |
Kevin T Conroy | director | 5505 ENDEAVOR LANE, MADISON WI 53719 |
Robert Hershberg | director | 3005 FIRST AVENUE, SEATTLE WA 98121 |
Peter M Neupert | director | 13920 SE EASTGATE WAY, STE 300, BELLEVUE WA 98005 |
Sharon Benzeno | officer: Chief Commercial Ofc Imm Med | C/O ADAPTIVE BIOTECHNOLOGIES CORPORATION, 1551 EASTLAKE AVE E STE 200, SEATTLE WA 98102 |
Harlan S Robins | officer: Chief Scientific Officer | C/O ADAPTIVE BIOTECHNOLOGIES CORPORATION, 1551 EASTLAKE AVE E STE 200, SEATTLE WA 98102 |
Francis Lo | officer: Chief People Officer | C/O ADAPTIVE BIOTECHNOLOGIES CORPORATION, 1551 EASTLAKE AVE E STE 200, SEATTLE WA 98102 |
Michael J Pellini | director | 222 DUTTON MILL RD, WILLISTOWN PA 19380 |
Chad M Robins | director, officer: CEO and Chairman | C/O ADAPTIVE BIOTECHNOLOGIES CORPORATION, 1551 EASTLAKE AVE E STE 200, SEATTLE WA 98102 |
From GuruFocus
By Marketwired • 11-07-2023
By Marketwired • 08-02-2023
By Stock market mentor Stock market mentor • 01-23-2023
By sperokesalga sperokesalga • 05-03-2023
By Marketwired • 11-02-2023
By Value_Insider Value_Insider • 11-21-2022
By PurpleRose PurpleRose • 07-12-2022
By sperokesalga sperokesalga • 05-24-2023
By Value_Insider Value_Insider • 11-21-2022
By PurpleRose PurpleRose • 07-28-2022
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.